OR WAIT null SECS
March 01, 2022
UCB has announced that it is extending its tender offer to acquire Zogenix.
February 28, 2022
EMA has recommended granting a marketing authorization in the EU for Kimmtrak (tebentafusp), a new medicine for a rare type of eye cancer.
EMA has recommended approval of Spikevax for children aged 6 to 11.
Johnson & Johnson has confirmed advancement of the nationwide opioid settlement agreement.
Pfizer and BioNTech receive positive opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in the EU.
February 25, 2022
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure.
February 24, 2022
FDA licenses Certara’s Immunogenicity Simulator to research and evaluate immunogenicity in protein-based therapeutics.
AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.
A new portfolio of chromatography and mass spectrometry consumables launched by Thermo Fisher Scientific is designed to meet higher performance requirements while remaining economical.
TFF Pharmaceuticals announces findings that inhaled niclosamide significantly inhibits viral replication of the Omicron variant of SARS-CoV-2.